J&J's Kenvue IPO prices at $22 per share.
TL;DR Summary
Johnson & Johnson's Kenvue unit is set to have the biggest IPO since 2021, with a valuation of over $40 billion. The IPO will raise more than all other IPOs combined that have made it to market in 2023. Kenvue will hold consumer brands such as Band-Aid, Tylenol, and Listerine. J&J will continue to own about 92% of Kenvue and plans to distribute the remaining shares to its own shareholders in a deal that may come in the second half of the year.
- Johnson & Johnson's Kenvue IPO to command valuation of more than $40 billion MarketWatch
- J&J spinoff Kenvue prices IPO at $22, toward the top end of expected range CNBC
- Johnson and Johnson IPO Today – Consumer Healthcare Unit Starts Trading at $22 TipRanks
- J&J’s Kenvue Prices IPO at $22 Per Share Yahoo Finance
- J&J Prices Consumer Unit IPO at $22 a Share The Wall Street Journal
Reading Insights
Total Reads
0
Unique Readers
0
Time Saved
2 min
vs 3 min read
Condensed
80%
421 → 83 words
Want the full story? Read the original article
Read on MarketWatch